The United Laboratories International Holdings Limited (3933.HK)
HKD 13.38
(0.45%)
HKD 13.38
(0.45%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 13.73 Billion CNY | 21.22% |
| 2022 | 11.33 Billion CNY | 16.81% |
| 2021 | 9.7 Billion CNY | 10.61% |
| 2020 | 8.77 Billion CNY | 4.53% |
| 2019 | 8.39 Billion CNY | 11.74% |
| 2018 | 7.51 Billion CNY | 10.02% |
| 2017 | 6.82 Billion CNY | 12.32% |
| 2016 | 6.07 Billion CNY | -5.71% |
| 2015 | 6.44 Billion CNY | 0.37% |
| 2014 | 6.42 Billion CNY | 7.55% |
| 2013 | 5.97 Billion CNY | 5.63% |
| 2012 | 5.65 Billion CNY | 9.07% |
| 2011 | 5.18 Billion CNY | -6.46% |
| 2010 | 5.54 Billion CNY | 35.56% |
| 2009 | 4.08 Billion CNY | 23.62% |
| 2008 | 3.3 Billion CNY | 36.04% |
| 2007 | 2.43 Billion CNY | 16.53% |
| 2006 | 2.08 Billion CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 7.17 Billion CNY | 0.0% |
| 2023 Q2 | 6.9 Billion CNY | 0.0% |
| 2023 Q4 | 6.83 Billion CNY | 0.0% |
| 2023 FY | 13.73 Billion CNY | 21.22% |
| 2022 Q2 | 5.18 Billion CNY | 0.0% |
| 2022 Q4 | 6.15 Billion CNY | 0.0% |
| 2022 FY | 11.33 Billion CNY | 16.81% |
| 2021 FY | 9.7 Billion CNY | 10.61% |
| 2021 Q4 | 4.98 Billion CNY | 0.0% |
| 2021 Q2 | 4.71 Billion CNY | 0.0% |
| 2020 FY | 8.77 Billion CNY | 4.53% |
| 2020 Q2 | 4.3 Billion CNY | 0.0% |
| 2020 Q4 | 4.46 Billion CNY | 0.0% |
| 2019 Q2 | 4.09 Billion CNY | 0.0% |
| 2019 Q4 | 4.3 Billion CNY | 0.0% |
| 2019 FY | 8.39 Billion CNY | 11.74% |
| 2018 Q2 | 3.79 Billion CNY | 0.0% |
| 2018 Q4 | 3.71 Billion CNY | 0.0% |
| 2018 FY | 7.51 Billion CNY | 10.02% |
| 2017 FY | 6.82 Billion CNY | 12.32% |
| 2017 Q2 | 3.33 Billion CNY | 0.0% |
| 2017 Q4 | 3.48 Billion CNY | 0.0% |
| 2016 Q4 | 3.11 Billion CNY | 0.0% |
| 2016 Q2 | 2.96 Billion CNY | 0.0% |
| 2016 FY | 6.07 Billion CNY | -5.71% |
| 2015 Q4 | 3.04 Billion CNY | 0.0% |
| 2015 FY | 6.44 Billion CNY | 0.37% |
| 2015 Q2 | 3.24 Billion CNY | 0.0% |
| 2014 FY | 6.42 Billion CNY | 7.55% |
| 2014 Q4 | 3.46 Billion CNY | 0.0% |
| 2014 Q2 | 2.96 Billion CNY | 0.0% |
| 2013 Q4 | 3.04 Billion CNY | 0.0% |
| 2013 Q2 | 2.96 Billion CNY | 0.0% |
| 2013 FY | 5.97 Billion CNY | 5.63% |
| 2012 Q3 | 1.41 Billion CNY | 0.0% |
| 2012 FY | 5.65 Billion CNY | 9.07% |
| 2012 Q4 | 1.49 Billion CNY | 5.71% |
| 2012 Q1 | 1.41 Billion CNY | 0.0% |
| 2012 Q2 | 1.41 Billion CNY | 0.0% |
| 2011 Q1 | 1.29 Billion CNY | 0.0% |
| 2011 FY | 5.18 Billion CNY | -6.46% |
| 2011 Q4 | 1.41 Billion CNY | 9.07% |
| 2011 Q3 | 1.29 Billion CNY | 0.0% |
| 2011 Q2 | 1.29 Billion CNY | 0.0% |
| 2010 Q1 | 1.38 Billion CNY | 0.0% |
| 2010 FY | 5.54 Billion CNY | 35.56% |
| 2010 Q4 | 1.29 Billion CNY | -6.46% |
| 2010 Q3 | 1.38 Billion CNY | 0.0% |
| 2010 Q2 | 1.38 Billion CNY | 0.0% |
| 2009 Q3 | 1.02 Billion CNY | 0.0% |
| 2009 Q2 | 1.02 Billion CNY | 0.0% |
| 2009 Q1 | 1.02 Billion CNY | 0.0% |
| 2009 FY | 4.08 Billion CNY | 23.62% |
| 2009 Q4 | 1.38 Billion CNY | 35.56% |
| 2008 FY | 3.3 Billion CNY | 36.04% |
| 2008 Q4 | 1.02 Billion CNY | 23.62% |
| 2008 Q3 | 826.76 Million CNY | 0.0% |
| 2008 Q1 | 826.76 Million CNY | 0.0% |
| 2008 Q2 | 826.76 Million CNY | 0.0% |
| 2007 Q2 | 607.73 Million CNY | 0.0% |
| 2007 Q1 | 607.73 Million CNY | 0.0% |
| 2007 FY | 2.43 Billion CNY | 16.53% |
| 2007 Q4 | 826.76 Million CNY | 36.04% |
| 2007 Q3 | 607.73 Million CNY | 0.0% |
| 2006 Q4 | 607.73 Million CNY | 16.53% |
| 2006 Q3 | 521.52 Million CNY | 0.0% |
| 2006 Q1 | 521.52 Million CNY | 0.0% |
| 2006 FY | 2.08 Billion CNY | 0.0% |
| 2006 Q2 | 521.52 Million CNY | 0.0% |
| 2005 Q4 | 521.52 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -5201.738% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | -30.488% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -23149.313% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -1652.802% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | -1329.315% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | -1204.79% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | -705.123% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -1598.154% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -3277.062% |
| SSY Group Limited | 6.46 Billion HKD | -112.593% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -2018.995% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | -836.088% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 94.919% |